FTC Orders Divestitures In Impax’s $700M CorePharma Buy

Overview


Raymond Jacobson represented Impax Laboratories Inc. in FTC review of its proposed $700 million buyout of CorePharma. The agency requested certain product divestitures, which will clear the way for Impax’s previously announced acquisition of Tower Holdings Inc. and its three subsidiaries — CorePharma, Amedra Pharmaceuticals LLC and Lineage Therapeutics Inc. — from private equity firm RoundTable Healthcare Partners.